Pathogenic mutations in BRCA1 and BRCA2 genes markedly increase the risk of breast
cancer and other cancers such as ovarian/fallopian tube, pancreatic, prostate, and …

Background: Female carriers of a BRCA1 or 2 germline mutation face a high lifetime risk to
develop breast and ovarian cancer. Risk-reducing surgery, such as prophylactic bilateral …

Purpose: To assess physician recommendations about the use of tamoxifen in
premenopausal BRCA1 and BRCA2 mutation carriers. Methods: We mailed surveys to a …

Background Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer
and may choose to undergo prophylactic bilateral total mastectomy. We investigated the …

Women who inherit a deleterious BRCA1 or BRCA2 mutation face substantially increased
risks of developing breast cancer, which is estimated at 70%. Although annual screening …

Comparative effectiveness research has become an integral part of health care planning in
most developed countries. In a simulated cohort of women, aged 30–65, who tested positive …

Annual MRI screening is recommended as an adjunct to mammography for BRCA1 and
BRCA2 mutation carriers. Prophylactic oophorectomy has been shown to decrease breast …

Relative to her risk of breast carcinoma, the woman with a BRCA1 or BRCA2 gene mutation
can be managed either by intensive screening (with or without chemoprevention) or by …

Background: In women with a family history of breast cancer, bilateral prophylactic
mastectomy is associated with a decreased risk of subsequent breast cancer of …

Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …